Hormonal
Triple incretin agonists (GLP-1R/GIPR/GCGR) produce superior body weight reduction (up to 24.2%) compared to dual or mono-agonists, approaching the efficacy of bariatric surgery.
Retatrutide, a once-weekly injection targeting three gut hormone receptors, has shown remarkable weight loss results (up to 24% in trials). While side effects like nausea are common, they are often manageable by starting with a lower dose. This therapy represents a significant advancement over older GLP-1 drugs, offering efficacy closer to bariatric surgery without the surgical risks.
In the phase 2 study for efficacy for obesity, after 48 weeks of treatment, retatrutide treatment induced a weight reduction of 15% or more in 60%, 75%, and 83% of the participants who received either 4, 8, or 12 mg of retatrutide, respectively... The highest dose, 12 mg, of retatrutide resulted in a mean weight reduction of 24.2% in obese participants after 48 weeks [102].
Why this rating
Based on Phase 2 clinical trials (n=several hundred), high quality but not yet Phase 3 long-term data.
Source
Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
Robert M. Gutgesell et al. · Diabetes Therapy · 2024
DOI 10.1007/s13300-024-01566-x
More from this paper
- Dual incretin agonists (GLP-1R/GIPR) such as tirzepatide offer superior weight loss and glycemic control compared to GLP-1 mono-agonists, with a safety profile comparable to mono-agonists.Strong
- GLP-1/Glucagon dual agonists (e.g., mazdutide, survodutide) produce greater weight loss and triglyceride reduction compared to GLP-1 mono-agonists.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →